Drug Type Bispecific antibody |
Synonyms + [2] |
Target |
Mechanism Ang2 inhibitors(Angiopoietin-2 inhibitors), VEGFR antagonists(Vascular endothelial growth factor receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Wet age-related macular degeneration | Phase 2 | US | 28 Oct 2020 | |
Wet age-related macular degeneration | Phase 2 | PR | 28 Oct 2020 |